Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Osteosarcoma 2Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

pembrolizumab 47Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 15Paclitaxel 14Cyclophosphamide 13Cisplatin 13Carboplatin 13Bevacizumab 12Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Leucovorin 10Irinotecan 10Fluorouracil 10Capecitabine 10trastuzumab deruxtecan 8fludarabine 8Pemetrexed 8Doxorubicin 8Cetuximab 8cemiplimab 7abemaciclib 7Trastuzumab 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × Disulfiram × Clear all
NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
45 enrolled
Sarcoma

Neoplasm Metastasis, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡